Form 4: Director Daniel Skovronsky Receives Myriad Genetics Equity

Director Daniel Skovronsky was granted 59,701 restricted stock units in Myriad Genetics, Inc. as part of the company's 2026 equity incentive plan.

Summary

• Director Daniel Skovronsky acquired 59,701 restricted stock units (RSUs) on June 4, 2026.
• The grant was issued under the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan.
• Each RSU represents a contingent right to receive one share of common stock.
• Following this transaction, the director's total beneficial ownership is 195,507 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• The grant aligns the director's interests with long-term shareholder value through equity-based compensation.

Negatives

• The issuance of new equity results in minor dilution to existing shareholders.

Risks

• Vesting is subject to the passage of time or the occurrence of the next annual meeting, which may be impacted by future corporate events.

Future Outlook

The RSUs vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices intended to incentivize leadership and ensure alignment with company performance in the biotechnology sector.

Comparison to Industry Standards

• The use of restricted stock units as a primary component of director compensation is consistent with standard practices among mid-cap biotechnology firms.
• The vesting schedule tied to annual meetings is a common mechanism to ensure director retention through the annual cycle.

Corporate Governance

Stakeholder Impact

• Shareholders experience minor dilution from the issuance of new equity units.

Next Steps

• Vesting of the 59,701 RSUs on the earlier of June 4, 2027, or the date of the next annual meeting.

Key Dates

Keywords

Myriad Genetics, MYGN, Form 4, Insider Transaction, Equity Incentive Plan, Director Compensation